Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
|Videos|May 19, 2020
A 69-Year-Old Man With Advanced Castrate-Resistant Prostate Cancer
Author(s)Jorge A. Garcia, MD, FACP
Jorge Garcia, MD, FACP, provides insight on the case of a 69-year-old man with mCRPC and assesses the classes of agents currently available as treatment options.
Advertisement
Case:A 69-Year-Old Man with Advanced Castrate Resistant Prostate Cancer
Initial presentation
- A 69-year-old man presented with intermittent back discomfort and loss of appetite
- PMH: hyperlipidemia controlled on a statin, no known family history of cancer
- PE: DRE revealed asymmetric, boggy prostate; otherwise unremarkable
Clinical Workup
- Biopsy with TRUS showed adenocarcinoma of prostate
- Stage T2N0M0
- Grade group 4
- Germline genetic testing: MLH1, MSH2, MSH6, PMS2, BRCA1/2, ATM, PALB2 and CHEK2
- Chest/abdominal/pelvic CT scan showed no evidence distant metastases or lymph node involvement
- Bone scan was negative
- PSA 24.9 ng/mL
Treatment and Follow-Up
- EBRT + ADT was started
- Follow up at 6 months, PSA 11.2 ng/mL
- At 12 months PSA 18.6 ng/mL
- Patient reported increasing back discomfort and difficulty walking
- Bone scan at that time showed multiple vertebral lesions at L3/L4
- Treatment with radium-223 dichloride was initiate
- 6 infusions were completed, treatment was well tolerated
Advertisement
Related to this article
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5